Acanthamoeba spp. is known to cause a sight-threatening Acanthamoeba keratitis (AK) and a usually fatal encephalitis called granulomatous amebic encephalitis (GAE). Though a successful prognosis of AK depends upon an early diagnosis, the availability of safer drugs to successfully treat AK remains a challenge. The rarity of AK has made the pharmaceutical industry reluctant to invest in the development of drugs against this vision threating keratitis. After AK was recognized as an orphan disease, a funded project, the Orphan Drug for AK (ODAK), the drug polyhexamethylene biguanide (PHMB) has been studied in Acanthamoeba polyphaga keratitis model [1]. There are reports that Acanthamoeba can persist causing an active infection despite treatment with chlorhexidine or PHMB [2]. Recent discoveries of cell surface receptors and druggable proteins in pathogenic variants of Acanthamoeba castellanii have revived the interest of repurposing of some anticholinergic drugs like atropine that are already used in non-infectious ocular disorders. The evidence of the presence of human-like muscarinic receptors in Acanthamoeba spp. [3], that are known targets of atropine, supports the possible forte of repurposing atropine and its structural analogs in AK. Furthermore, very convincing indications have come from retrospective studies where atropine was reported to treat cases of AK without the use of any concurrent anti-amebic agents [4, 5]. Since atropine is already given as an adjuvant drug in cases of AK, this novel action of atropine has the potential to make it the drug of choice in AK if large-scale human trials provide definitive results.
Atropine used in AK could have a clear superiority over the newer drugs as it is already known for its safety in the eye and is in use for diverse ocular indications. Atropine and analogs like dicyclomine and pirenzepine that have proven to be amoebicidal in Acanthamoeba castellanii in vitro [3] (Fig. 1) could also be investigated for their use in AK in an animal model of this disease. Dicyclomine and pirenzepine, of which the latter is a more specific muscarinic M1 receptor (mAChR1) antagonist, have proven to be more effective amoebicidal agents in doses lower than atropine in vitro studies [5] (Fig. 1d), but these drugs need to be evaluated for their ocular safety and efficacy in animal model and in human trials. Use of eye drops containing polyethylene glycol 400 0.4% and propylene glycol 0.3% have also been reported to be amoebicidal and cysticidal. A decrease in the mitochondrial membrane potential and ATP levels  were shown to induce chromatin condensation in Acanthamoeba spp. in a study showing the toxic effects of selected proprietary dry eye drops [6].
AK, wound infection and GAE are notorious illnesses that are caused by Acanthamoeba spp., which are resistant to many anti-amebic drugs used at present. The prognosis of infections caused by this protist pathogen is very poor, which almost always results in blindness in AK (Fig. 2) and death in GAE. Development of new drugs is challenging and difficult as it takes a very long period to evaluate them for their safety and efficacies. Acetylcholine is known to stimulated the growth and proliferation of Acanthamoeba castellanii (Fig. 2a) [3] and anticholinergics like atropine, dicyclomine and pirenzepine antagonize strong proliferative signals generated from mAChR1 receptors (Fig. 2a) to exert an amoebicidal and cysticidal effects [3, 4]. These drugs offer a unique opportunity to repurpose them for their utility in AK [5] which is known to be common in contact lens users (Fig. 2b). Anticholinergic approved by FDA and their synthetic structural analogs could be speedily brought to human trials and clinical utility in infections like AK and GAE caused by Acanthamoeba spp.
References
Schlander Michael, Holm Søren, Nord Erik, Richardson Jeff, Garattini Silvio, Kolominsky-Rabas Peter, et al. 8th European Conference on Rare Diseases & Orphan Products (ECRD 2016). Orphanet J Rare Dis. 2016;11(Suppl 1):1–9. https://doi.org/10.1186/s13023-016-0515-y.
Seal DV. Acanthamoeba keratitis update-incidence, molecular epidemiology and new drugs for treatment. Eye (Lond). 2003;17:893–905.
Baig AM, Ahmad HR. (2017). Evidence of a M1-Muscarinic GPCR homolog in unicellular eukaryotes: featuring Acanthamoeba spp bioinformatics 3D-modelling and experimentations. J Recept Signal Transduct Res. 2017;7:1–9.
Agahan AL, Lim RB, Valenton MJ. Successful treatment of Acanthamoeba keratitis without anti-amoebic agents. Ann Acad Med Singap. 2009;38:175–17.
Baig AM, Hareem Z, Khan NA. Recommendations for the management of Acanthamoeba keratitis. J Med Microbiol. 2014; https://doi.org/10.1099/jmm.0.069237-0.
Sifaoui I, Reyes-Batlle M, López-Arencibia A, Chiboub O, RodrÃguez-MartÃn J, Rocha-Cabrera P et al. Toxic effects of selected proprietary dry eye drops on Acanthamoeba. Sci Rep. 2018;8:8520. https://doi.org/10.1038/s41598-018-26914-3.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The author declares that he has no conflict of interest. The author has not received any assistance in writing this paper and has no associations with the pharmaceutical companies. This project has been partly funded by Aga Khan University Pakistan.
Rights and permissions
About this article
Cite this article
Baig, A. Drug targeting in Acanthamoeba keratitis: rational of using drugs that are already approved for ocular use in non-keratitis indications. Eye 33, 509–518 (2019). https://doi.org/10.1038/s41433-018-0245-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41433-018-0245-6